M&A · Healthcare · Electromedical & Electrotherapeutic Apparatus
Repligen Corp to acquire Biolife Solutions Inc
Announced Jul 22, 2026 · Closed Oct 6, 2026
Deal value$1.50BEV $1.50B
Premium6.2%To unaffected price
EV / Adj. EBITDA—15.0x EV / Revenue
ConsiderationCash and stock$31.00 per share
Transaction
- Acquirer
- Repligen Corp (RGEN)
- Target
- Biolife Solutions Inc
- Buyer type
- Strategic
- Offer price per share
- $31.00
- Enterprise value
- $1.50B
- Status
- Closed Oct 6, 2026
Deal protections
- Break fee (target pays)
- $59.0M · 3.9%
- Reverse fee (buyer pays)
- —
- Go-shop
- No-shop
- Financing
- No financing condition
Advisors
- To the acquirer
- Perella Weinberg, Goldman Sachs
- To the target
- Centerview
Sector context · Healthcare
- Comparable deals
- 102 in the prior 24 months
- Premium
- 6.2% vs. 48.0% sector median
- EV / Adj. EBITDA
- Sector median 10.9x
- Break fee
- 3.9% vs. 3.5% sector median
Timeline
- AnnouncedJul 22, 2026
- Proxy filedSep 4, 2026
- Definitive proxySep 4, 2026
- Shareholder voteOct 6, 2026
- ClosedOct 6, 2026
Valuation · fairness opinions
Trading comparables$22.65$27.20
Trading comparables$132.35$160.85
Precedent transactions$25.35$33.75
Discounted cash flow$26.40$33.65
Discounted cash flow$126.70$156.70
Offer $31.00
Implied value per Biolife Solutions Inc share by analysis, from Centerview.